Trial · NCT01590160
Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
NCT01590160, Phase 1, Phase 2, Completed, University College, London
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma. Trials, record NCT01590160. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01590160
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
- NCT number
- NCT01590160
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 27 participants, actual
- Lead sponsor
- University College, London
- Conditions
- Lung Cancer - Malignant Pleural Mesothelioma
- Interventions
- Ganetespib
- First posted
- 2012-05-02
- Last updated
- 2019-11-13
- Other registries' IDs
- eudract:2012-001598-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose of Ganetespib | 6 Months | Primary endpoint (phase I): Dose-limiting toxicities during Cycles 1 \& 2; and number of cycles of pemetrexed-cisplatin given. The Phase I trial will consist of three ganetespib dose cohorts, each with 3 or 6 patients: * Cohort 1: 100mg/m2 IV on day 1 and day 15 of each cycle * Cohort 2: 150mg/m2 IV on day 1 and day 15 of each cycle * Cohort 3: 200mg/m2 IV on day 1 and day 15 of each cycle There will be additional patients to be treated with carboplatin (AUC5) instead of cisplatin. If treatment with carboplatin is confirmed to be safe and tolerable, the option of treating patients with either cisplatin or carboplatin during phase II will be taken. The evaluation will be done using an accelerated titrated phase I design. Primary endpoint (phase II): Progression free survival |
| Secondary | Progression Free Survival | 24 Months | Secondary endpoints (phase I): * To examine the number of cycles of pemetrexed/platinum chemotherapy administered. * To examine the objective tumour response according to meso-modified RECIST, and the overall response rate. Secondary endpoints (phase II): * To examine the frequency of all Adverse Events graded by NCI-CTCAE version 4, in particular those with grade 3 or 4 events. * To examine the objective tumour response according to meso-modified RECIST, and the overall response rate. * To examine overall survival. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32669375 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01590160
GET https://conductscience.org/api/trials/v1/NCT01590160/registered